Clinical Trial Update: Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing camrelizumab plus stereotactic body radiotherapy versus camrelizumab alone in oligometastatic nasopharyngeal carcinoma is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING